244 related articles for article (PubMed ID: 36716576)
1. Electronic health record data for assessing risk of hospitalization for COVID-19: Methodological considerations applied to multiple sclerosis.
Dillon P; Siadimas A; Roumpanis S; Fajardo O; Fitovski K; Jessop N; Whitley L; Muros-Le Rouzic E
Mult Scler Relat Disord; 2023 Mar; 71():104512. PubMed ID: 36716576
[TBL] [Abstract][Full Text] [Related]
2. Dimethyl fumarate is associated with lower rates of infection and lower infection-related healthcare costs when compared with ocrelizumab.
Nicholas JA; Gudesblatt M; Garabedian M; Belviso N; Shen C; Geremakis C; Shankar SL; Mendoza JP; Lewin JB
Mult Scler Relat Disord; 2022 Jul; 63():103921. PubMed ID: 35700674
[TBL] [Abstract][Full Text] [Related]
3. COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies.
Reder AT; Centonze D; Naylor ML; Nagpal A; Rajbhandari R; Altincatal A; Kim M; Berdofe A; Radhakrishnan M; Jung E; Sandrock AW; Smirnakis K; Popescu C; de Moor C
CNS Drugs; 2021 Mar; 35(3):317-330. PubMed ID: 33743151
[TBL] [Abstract][Full Text] [Related]
4. Risk of Getting COVID-19 in People With Multiple Sclerosis: A Case-Control Study.
Iaffaldano P; Lucisano G; Manni A; Paolicelli D; Patti F; Capobianco M; Brescia Morra V; Sola P; Pesci I; Lus G; De Luca G; Lugaresi A; Cavalla P; Montepietra S; Maniscalco GT; Granella F; Ragonese P; Vianello M; Brambilla L; Totaro R; Toscano S; Malucchi S; Petracca M; Moiola L; Ferraro D; Lepore V; Mosconi P; Ponzio M; Tedeschi G; Comi G; Battaglia MA; Filippi M; Amato MP; Trojano M;
Neurol Neuroimmunol Neuroinflamm; 2022 Mar; 9(2):. PubMed ID: 35046084
[TBL] [Abstract][Full Text] [Related]
5. Vaccine-based clinical protection against SARS-CoV-2 infection and the humoral immune response: A 1-year follow-up study of patients with multiple sclerosis receiving ocrelizumab.
Räuber S; Willison A; Korsen M; Kölsche T; Golombeck KS; Plaack B; Schüller J; Huntemann N; Rolfes L; Schroeter CB; Nelke C; Regner-Nelke L; Förster M; Ringelstein M; Barnett MH; Hartung HP; Aktas O; Albrecht P; Ruck T; Melzer N; Meuth SG; Kremer D
Front Immunol; 2022; 13():1037214. PubMed ID: 36618356
[TBL] [Abstract][Full Text] [Related]
6. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
7. Real-World Clinical and Economic Outcomes Among Persons With Multiple Sclerosis Initiating First- Versus Second- or Later-Line Treatment With Ocrelizumab.
Geiger CK; Sheinson D; To TM; Jones D; Bonine NG
Neurol Ther; 2023 Oct; 12(5):1709-1728. PubMed ID: 37458897
[TBL] [Abstract][Full Text] [Related]
8. Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis.
Simpson-Yap S; De Brouwer E; Kalincik T; Rijke N; Hillert JA; Walton C; Edan G; Moreau Y; Spelman T; Geys L; Parciak T; Gautrais C; Lazovski N; Pirmani A; Ardeshirdavanai A; Forsberg L; Glaser A; McBurney R; Schmidt H; Bergmann AB; Braune S; Stahmann A; Middleton R; Salter A; Fox RJ; van der Walt A; Butzkueven H; Alroughani R; Ozakbas S; Rojas JI; van der Mei I; Nag N; Ivanov R; Sciascia do Olival G; Dias AE; Magyari M; Brum D; Mendes MF; Alonso RN; Nicholas RS; Bauer J; Chertcoff AS; Zabalza A; Arrambide G; Fidao A; Comi G; Peeters L
Neurology; 2021 Nov; 97(19):e1870-e1885. PubMed ID: 34610987
[TBL] [Abstract][Full Text] [Related]
9. Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis.
Sormani MP; De Rossi N; Schiavetti I; Carmisciano L; Cordioli C; Moiola L; Radaelli M; Immovilli P; Capobianco M; Trojano M; Zaratin P; Tedeschi G; Comi G; Battaglia MA; Patti F; Salvetti M;
Ann Neurol; 2021 Apr; 89(4):780-789. PubMed ID: 33480077
[TBL] [Abstract][Full Text] [Related]
10. Six-month humoral response to mRNA SARS-CoV-2 vaccination in patients with multiple sclerosis treated with ocrelizumab and fingolimod.
Capuano R; Bisecco A; Conte M; Donnarumma G; Altieri M; Grimaldi E; Franci G; Chianese A; Galdiero M; Coppola N; Tedeschi G; Gallo A
Mult Scler Relat Disord; 2022 Apr; 60():103724. PubMed ID: 35272145
[TBL] [Abstract][Full Text] [Related]
11. Comparative effectiveness of dimethyl fumarate versus fingolimod and teriflunomide among MS patients switching from first-generation platform therapies in the US.
Ontaneda D; Nicholas J; Carraro M; Zhou J; Hou Q; Babb J; Riester K; Mendoza JP; Livingston T; Jhaveri M
Mult Scler Relat Disord; 2019 Jan; 27():101-111. PubMed ID: 30368221
[TBL] [Abstract][Full Text] [Related]
12. Indirect impact of the COVID-19 pandemic on the care and outcomes of people with MS: A combined survey and insurance claims study.
Meltzer E; Charron O; Wozny J; Onuorah H; Montague A; Kline AC; Largent A; Krause TM; Freeman L
Mult Scler Relat Disord; 2023 Dec; 80():105085. PubMed ID: 37931487
[TBL] [Abstract][Full Text] [Related]
13. COVID-19 in ocrelizumab-treated people with multiple sclerosis.
Hughes R; Whitley L; Fitovski K; Schneble HM; Muros E; Sauter A; Craveiro L; Dillon P; Bonati U; Jessop N; Pedotti R; Koendgen H
Mult Scler Relat Disord; 2021 Apr; 49():102725. PubMed ID: 33482590
[TBL] [Abstract][Full Text] [Related]
14. Risk of breakthrough COVID-19 after vaccination among people with multiple sclerosis on disease-modifying therapies.
Spierer R; Lavi I; Bloch S; Mazar M; Golan D
J Neurol; 2023 Oct; 270(10):4632-4639. PubMed ID: 37589743
[TBL] [Abstract][Full Text] [Related]
15. Symptomatic COVID-19 course and outcomes after three mRNA vaccine doses in multiple sclerosis patients treated with high-efficacy DMTs.
Capuano R; Prosperini L; Altieri M; Lorefice L; Fantozzi R; Cavalla P; Guaschino C; Radaelli M; Cordioli C; Nociti V; Boffa L; Ragonese P; Di Gregorio M; Pinardi F; Torri Clerici V; De Luca G; Gajofatto A; Paolicelli D; Tortorella C; Gasperini C; Solaro C; Cocco E; Bisecco A; Gallo A
Mult Scler; 2023 Jun; 29(7):856-865. PubMed ID: 37165941
[TBL] [Abstract][Full Text] [Related]
16. COVID-19 infection and hospitalization rate in Iranian multiple sclerosis patients: What we know by May 2021.
Naghavi S; Kavosh A; Adibi I; Shaygannejad V; Arabi S; Rahimi M; Mazaheri S; Ashtari F
Mult Scler Relat Disord; 2022 Jan; 57():103335. PubMed ID: 35158427
[TBL] [Abstract][Full Text] [Related]
17. Impact of the COVID-19 pandemic on the health care of >1,000 People living with multiple sclerosis: A cross-sectional study.
Vogel AC; Schmidt H; Loud S; McBurney R; Mateen FJ
Mult Scler Relat Disord; 2020 Nov; 46():102512. PubMed ID: 32977074
[TBL] [Abstract][Full Text] [Related]
18. Potential beneficial effect of IFN-β1a and ocrelizumab in people with MS during the COVID-19 pandemic.
Todorović S; Vojinović S; Savić D; Aleksić D; Danilović M
Acta Neurol Belg; 2024 Apr; 124(2):447-455. PubMed ID: 37962785
[TBL] [Abstract][Full Text] [Related]
19. Comparative Efficacy and Safety of Ozanimod and Dimethyl Fumarate for Relapsing-Remitting Multiple Sclerosis Using Matching-Adjusted Indirect Comparison.
Cohan S; Kumar J; Arndorfer S; Zhu X; Zivkovic M; Tencer T
CNS Drugs; 2021 Jul; 35(7):795-804. PubMed ID: 33847901
[TBL] [Abstract][Full Text] [Related]
20. Does pandemic change the ocrelizumab therapy approach? Yes. - Single center ocrelizumab experience.
Tezer DÇ; Dogan IG; Atmaca MC; Atmaca MM; Demir S
Ideggyogy Sz; 2022 Nov; 75(11-12):411-417. PubMed ID: 36541145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
